Agreed... one partner would be the launch-pad to bring several things about. SP increase, available cash/favourable balance sheet in the revenue dept, and also would serve as a potential safety-signal for additional partners. Having a product sale would accomplish similar goals, with an individual license of a formulation for a specific indication of B; enabling them to post some revenue, drive SP, and then proceed to uplist. Once uplisted, they're on the open market for institutional investing which is the other wildcard to drive SP. Sky's sort of the limit here.